(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement today:

“The industry trade association representing America’s pharmacy benefit companies reiterates its position that, to date, the Federal Trade Commission (FTC) has fallen far short of providing a definitive, fact-based assessment of pharmacy benefit managers (PBMs) or the prescription drug market. Members of the commission themselves disagree with what the FTC has released this year about the PBM industry.

“Anecdotes and comments from anonymous sources and self-interested parties, supported only by cherry-picked case studies that are implied to be representative of the entire market, is damaging to our companies’ ability to rein in costs for the employers and patients we serve, driving costs up everywhere in the healthcare system and helping only Big Pharma.

“The FTC has a history as an objective agency that relies on data and evidence. The FTC and Congress must not ignore the volumes of data that demonstrate the value that PBMs provide to America’s health care system by reducing prescription drug costs and increasing access to medications.”

###

PCMA is the national association representing America’s pharmacy benefit companies. Pharmacy benefit companies are working every day to secure savings, enable better health outcomes, and support access to quality prescription drug coverage for more than 275 million patients.